Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) has recently gained attention as an anti-protozoan and anti-cancer drug target. We have previously identified 2-phenoxy-1,4-naphthoquinone as an inhibitor of both Trypanosoma brucei and human GAPDH. Herein, through multiple chemical, biochemical, and biological studies, and through the design of analogs, we confirmed the formation of a covalent adduct, we clarified the inhibition mechanism and we demonstrated antitrypanosomal, antiplasmodial and cytotoxic activities in cell cultures. The overall results lent support to the hypothesis that 2-phenoxy-1,4-naphthoquinone binds the GAPDH catalytic cysteine covalently through a phenolate displacement mechanism. By investigating the reactivity of 2-phenoxy-1,4-naphthoquinone and its analogs with four GAPDH homologs, we showed that the covalent inhibition is not preceded by the formation of a strong non-covalent complex. However, an up to 5-fold difference in inactivation rates among homologs hinted at structural or electrostatic differences of their active sites that could be exploited to further design kinetically selective inhibitors. Moreover, we preliminarily showed that 2-phenoxy-1,4-naphthoquinone displays selectivity for GAPDHs over two other cysteine-dependent enzymes, supporting its suitability as a warhead starting fragment for the design of novel inhibitors. This article is protected by copyright. All rights reserved.

Molecular basis for covalent inhibition of glyceraldehyde-3-phosphate dehydrogenase by a 2-phenoxy-1,4-naphthoquinone small molecule / Bruno, Stefano; Uliassi, Elisa; Zaffagnini, Mirko; Prati, Federica; Bergamini, Christian; Amorati, Riccardo; Paredi, Gianluca; Margiotta, Marilena; Conti, Paola; Costi, Maria Paola; Kaiser, Marcel; Cavalli, Andrea; Fato, Romana; Bolognesi, Maria Laura. - In: CHEMICAL BIOLOGY & DRUG DESIGN. - ISSN 1747-0277. - ELETTRONICO. - 89:(2017), pp. 1-11. [10.1111/cbdd.12941]

Molecular basis for covalent inhibition of glyceraldehyde-3-phosphate dehydrogenase by a 2-phenoxy-1,4-naphthoquinone small molecule

BRUNO, STEFANO;ULIASSI, ELISA;ZAFFAGNINI, MIRKO;PRATI, FEDERICA;BERGAMINI, CHRISTIAN;AMORATI, RICCARDO;CAVALLI, ANDREA;FATO, ROMANA;BOLOGNESI, MARIA LAURA
2017

Abstract

Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) has recently gained attention as an anti-protozoan and anti-cancer drug target. We have previously identified 2-phenoxy-1,4-naphthoquinone as an inhibitor of both Trypanosoma brucei and human GAPDH. Herein, through multiple chemical, biochemical, and biological studies, and through the design of analogs, we confirmed the formation of a covalent adduct, we clarified the inhibition mechanism and we demonstrated antitrypanosomal, antiplasmodial and cytotoxic activities in cell cultures. The overall results lent support to the hypothesis that 2-phenoxy-1,4-naphthoquinone binds the GAPDH catalytic cysteine covalently through a phenolate displacement mechanism. By investigating the reactivity of 2-phenoxy-1,4-naphthoquinone and its analogs with four GAPDH homologs, we showed that the covalent inhibition is not preceded by the formation of a strong non-covalent complex. However, an up to 5-fold difference in inactivation rates among homologs hinted at structural or electrostatic differences of their active sites that could be exploited to further design kinetically selective inhibitors. Moreover, we preliminarily showed that 2-phenoxy-1,4-naphthoquinone displays selectivity for GAPDHs over two other cysteine-dependent enzymes, supporting its suitability as a warhead starting fragment for the design of novel inhibitors. This article is protected by copyright. All rights reserved.
2017
Molecular basis for covalent inhibition of glyceraldehyde-3-phosphate dehydrogenase by a 2-phenoxy-1,4-naphthoquinone small molecule / Bruno, Stefano; Uliassi, Elisa; Zaffagnini, Mirko; Prati, Federica; Bergamini, Christian; Amorati, Riccardo; Paredi, Gianluca; Margiotta, Marilena; Conti, Paola; Costi, Maria Paola; Kaiser, Marcel; Cavalli, Andrea; Fato, Romana; Bolognesi, Maria Laura. - In: CHEMICAL BIOLOGY & DRUG DESIGN. - ISSN 1747-0277. - ELETTRONICO. - 89:(2017), pp. 1-11. [10.1111/cbdd.12941]
Bruno, Stefano; Uliassi, Elisa; Zaffagnini, Mirko; Prati, Federica; Bergamini, Christian; Amorati, Riccardo; Paredi, Gianluca; Margiotta, Marilena; Conti, Paola; Costi, Maria Paola; Kaiser, Marcel; Cavalli, Andrea; Fato, Romana; Bolognesi, Maria Laura
File in questo prodotto:
Eventuali allegati, non sono esposti

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11585/588459
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? 5
  • Scopus 14
  • ???jsp.display-item.citation.isi??? 14
social impact